2. Academic Validation
  3. Protocol for identifying properties of ERBB receptor antagonists using the barcoded ERBBprofiler assay

Protocol for identifying properties of ERBB receptor antagonists using the barcoded ERBBprofiler assay

  • STAR Protoc. 2024 Apr 16;5(2):102987. doi: 10.1016/j.xpro.2024.102987.
Lukša Popović 1,  Moritz J Rossner 2,  Michael C Wehr 3
Affiliations

Affiliations

  • 1 Research Group Cell Signalling, Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Nussbaumstr. 7, 80336 Munich, Germany; Systasy Bioscience GmbH, Balanstr. 6, 81669 Munich, Germany.
  • 2 Systasy Bioscience GmbH, Balanstr. 6, 81669 Munich, Germany; Section of Molecular Neurobiology, Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Nussbaumstr. 7, 80336 Munich, Germany.
  • 3 Research Group Cell Signalling, Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Nussbaumstr. 7, 80336 Munich, Germany; Systasy Bioscience GmbH, Balanstr. 6, 81669 Munich, Germany. Electronic address: michael.wehr@med.uni-muenchen.de.
PMID: 38635397 DOI: 10.1016/j.xpro.2024.102987
Abstract

The ERBBprofiler assay measures compound effects on ERBB family receptors and key downstream signaling pathways that are implicated in Cancer or Other complex diseases. Here, we present a protocol for identifying properties of ERBB receptor antagonists using the barcoded ERBBprofiler assay. We describe steps for in-solution transfection, cell treatment, combined processing of samples, amplification and indexing of PCRs, Sequencing, and data analysis. This approach allows for the simultaneous assessment of drug effects and cell-type-dependent effects. For complete details on the use and execution of this protocol, please refer to Popović et al.1.

Keywords

Cancer; Cell culture; Cell-based Assays.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-104065
    99.89%, EGFR/HER2 Inhibitor